TrialPloS one2021

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients.

Namrata S Patil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.